rs113994095
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PP5_Very_Strong
The NM_002693.3(POLG):c.1399G>A(p.Ala467Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00101 in 1,614,256 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.00066 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0011 ( 0 hom. )
Consequence
POLG
NM_002693.3 missense
NM_002693.3 missense
Scores
6
10
3
Clinical Significance
Conservation
PhyloP100: 7.47
Genes affected
POLG (HGNC:9179): (DNA polymerase gamma, catalytic subunit) Mitochondrial DNA polymerase is heterotrimeric, consisting of a homodimer of accessory subunits plus a catalytic subunit. The protein encoded by this gene is the catalytic subunit of mitochondrial DNA polymerase. The encoded protein contains a polyglutamine tract near its N-terminus that may be polymorphic. Defects in this gene are a cause of progressive external ophthalmoplegia with mitochondrial DNA deletions 1 (PEOA1), sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO), Alpers-Huttenlocher syndrome (AHS), and mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE). Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
PP5
Variant 15-89327201-C-T is Pathogenic according to our data. Variant chr15-89327201-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 13496.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr15-89327201-C-T is described in Lovd as [Pathogenic]. Variant chr15-89327201-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| POLG | NM_002693.3 | c.1399G>A | p.Ala467Thr | missense_variant | 7/23 | ENST00000268124.11 | NP_002684.1 | |
| POLGARF | NM_001406557.1 | c.*671G>A | 3_prime_UTR_variant | 7/23 | NP_001393486.1 | |||
| POLG | NM_001126131.2 | c.1399G>A | p.Ala467Thr | missense_variant | 7/23 | NP_001119603.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| POLG | ENST00000268124.11 | c.1399G>A | p.Ala467Thr | missense_variant | 7/23 | 1 | NM_002693.3 | ENSP00000268124 | P1 |
Frequencies
GnomAD3 genomes 0.000657 AC: 100AN: 152254Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
100
AN:
152254
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000513 AC: 129AN: 251484Hom.: 0 AF XY: 0.000522 AC XY: 71AN XY: 135918
GnomAD3 exomes
AF:
AC:
129
AN:
251484
Hom.:
AF XY:
AC XY:
71
AN XY:
135918
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00105 AC: 1537AN: 1461884Hom.: 0 Cov.: 34 AF XY: 0.00103 AC XY: 748AN XY: 727244
GnomAD4 exome
AF:
AC:
1537
AN:
1461884
Hom.:
Cov.:
34
AF XY:
AC XY:
748
AN XY:
727244
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome 0.000656 AC: 100AN: 152372Hom.: 0 Cov.: 33 AF XY: 0.000617 AC XY: 46AN XY: 74514
GnomAD4 genome
AF:
AC:
100
AN:
152372
Hom.:
Cov.:
33
AF XY:
AC XY:
46
AN XY:
74514
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
1
ALSPAC
AF:
AC:
6
ESP6500AA
AF:
AC:
4
ESP6500EA
AF:
AC:
12
ExAC
AF:
AC:
63
Asia WGS
AF:
AC:
2
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:49Other:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:16
| Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 03, 2023 | The POLG c.1399G>A; p.Ala467Thr variant (rs113994095) is reported in association with recessive forms of disease. This variant is one of the most common pathogenic variants in POLG (Cohen 2018) and is reported in the literature in the homozygous or compound heterozygous state in numerous individuals affected with POLG-related disorders (Horvath 2006, Luoma 2005, Tzoulis 2006, Van Goethem 2001). This variant is also reported as pathogenic in ClinVar (Variation ID: 13496) and is found in the general population with an overall allele frequency of 0.05% (143/282,888 alleles) in the Genome Aggregation Database (v2.1.1). Computational analyses predict that this variant is deleterious (REVEL: 0.884). Functional studies of the variant protein suggest it has reduced affinity for DNA and has significantly decreased polymerase activity compared to wildtype POLG (Chan 2005, Luoma 2006). Based on available information, this variant is considered to be pathogenic. References: Chan SS et al. The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit. J Biol Chem. 2005 Sep 9;280(36):31341-6. PMID: 16024923. Cohen BH et al. POLG-Related Disorders. GeneReviews. 2018. (https://www.ncbi.nlm.nih.gov/books/NBK26471/). PMID: 20301791. Horvath R et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain. 2006 Jul;129(Pt 7):1674-84. PMID: 16621917. Luoma PT et al. Functional defects due to spacer-region mutations of human mitochondrial DNA polymerase in a family with an ataxia-myopathy syndrome. Hum Mol Genet. 2005 Jul 15;14(14):1907-20. PMID: 15917273. Tzoulis C et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain. 2006 Jul;129(Pt 7):1685-92. PMID: 16638794. Van Goethem G et al. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet. 2001 Jul;28(3):211-2. PMID: 11431686. - |
| Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Mar 01, 2024 | POLG: PM3:Very Strong, PP1:Strong, PS3, PM2 - |
| Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jul 07, 2022 | PP3, PM2, PM3, PS3, PS4_moderate - |
| Pathogenic, no assertion criteria provided | clinical testing | Genetic Services Laboratory, University of Chicago | Sep 03, 2022 | DNA sequence analysis of the POLG gene demonstrated a sequence change, c.1399G>A, in exon 7 that results in an amino acid change, p.Ala467Thr. The p.Ala467Thr change affects a highly conserved amino acid residue located in a domain of the POLG protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Ala467Thr substitution. This pathogenic sequence change has previously been described as the most common POLG variant associated with autosomal recessive Alpers-Huttenlocher syndrome (PMID: 20301791). This sequence change has been associated with reduced enzyme activity (PMID: 20301791). This sequence change has been described in the gnomAD database with a frequency of 0.05% in the overall population (dbSNP rs113994095). These collective evidences indicate that this sequence change is pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Sep 07, 2022 | The frequency of this variant in the general population is consistent with pathogenicity ((Genome Aggregation Database (gnomAD), Cambridge, MA (URL: http://gnomad.broadinstitute.org)). This variant has been identified in multiple individuals with different autosomal recessive POLG-related disorders. Assessment of experimental evidence suggests this variant results in abnormal protein function. In an in vitro study, this variant abrogated polymerase activity, processivity, and exonuclease activity (PMID: 27987238). In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. - |
| Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Oct 23, 2020 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Mar 17, 2022 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 21, 2017 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 25, 2019 | Identified in individuals with autosomal recessive progressive external ophthalmoplegia (arPEO) and has subsequently been identified in patients with Alpers syndrome, sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO), and other POLG-related disorders causing epilepsy, ataxia, neuropathy, hepatopathy, and/or myopathy (vanGoethem et al., 2001); Published functional studies demonstrate a damaging effect (Kasahara et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 22616202, 16368709, 11431686, 20837861, 21235791, 21686371, 22189570, 21515089, 22342071, 23448099, 22995991, 15917273, 21993618, 23212759, 18500570, 23430834, 24272679, 23783014, 20576279, 20691285, 20818383, 22931735, 22006280, 21647632, 25286830, 20138553, 21880868, 16024923, 26104464, 26735972, 27987238, 15122711, 15824347, 18783964, 19501198, 19766516, 28771251, 19813183, 19538466, 29588995, 18546343, 24725338, 29655203, 30167885, 30423451, 30369941, 27422324, 31980526, 31589614, 33473333) - |
| Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jul 17, 2023 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Dec 07, 2023 | - - |
Progressive sclerosing poliodystrophy Pathogenic:8
| Pathogenic, criteria provided, single submitter | clinical testing | Wong Mito Lab, Molecular and Human Genetics, Baylor College of Medicine | Oct 01, 2018 | The NM_002693.2:c.1399G>A (NP_002684.1:p.Ala467Thr) [GRCH38: NC_000015.10:g.89327201C>T] variant in POLG gene is interpretated to be a Pathogenic based on ACMG guidelines (PMID: 25741868). This variant meets the following evidence codes reported in the ACMG-guideline. PS3:Well established functional studies show a deleterious effect on POLG. PS4:Prevalence of variant in affecteds statistically increased over controls. PM3:Detected in trans with a pathogenic variant for Mitochondrial DNA depletion syndrome 4A (Alpers type) which is a recessive disorder. PP1:This variant is co-segregated with Mitochondrial DNA depletion syndrome 4A (Alpers type) in multiple affected family members. PP4:Patient's phenotype or family history is highly specific for POLG. PP5:Reputable source(s) suggest that the variant is pathogenic. Based on the evidence criteria codes applied, the variant is suggested to be Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 27, 2024 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Undiagnosed Diseases Network, NIH | Jan 03, 2018 | This is the most common pathogenic variant described in cases of Alpers-Huttenlocher syndrome (Mitochondrial DNA depletion syndrome 4A (Alpers type), MIM 203700), we have sparse records on the patient's phenotype (long deceased), but it seems a very reasonable clinical fit, albeit perhaps somewhat late onset (age 11). - |
| Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 467 of the POLG protein (p.Ala467Thr). This variant is present in population databases (rs113994095, gnomAD 0.09%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with autosomal recessive POLG-related disorders, Alpers-Huttenlocher syndrome, autosomal recessive progressive external ophthalmoplegia, sensory ataxic neuropathy, dysarthria and ophthalmoplegia (SANDO), and other POLG-related disorders causing epilepsy, ataxia, neuropathy, hepatopathy, and myopathy (PMID: 11431686, 15122711, 15917273, 20691285, 25286830, 26735972). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 13496). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on POLG protein function. Experimental studies have shown that this missense change affects POLG function (PMID: 15917273, 16024923). For these reasons, this variant has been classified as Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Jul 22, 2020 | 0102 - Loss of function is a known mechanism of disease in this gene and is associated with POLG-related mitochondrial disorders. (I) 0108 - This gene is associated with both recessive and dominant disease. Variants in this gene predominantly cause recessive disease however, progressive external ophthalmoplegia can also be dominantly inherited (OMIM). (I) 0112 - Autosomal dominant progressive external ophthalmoplegia associated with this gene has incomplete penetrance (OMIM). (I) 0200 - Variant is predicted to result in a missense amino acid change from alanine to threonine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (v2: 143 heterozygotes, 0 homozygotes). (SP) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0600 - Variant is located in the linker region (PMID: 16024923). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This is one of the most reported variants predominantly in homozygous and compound heterozygous individuals with mitochondrial DNA depletion syndrome 4A (Alpers type) (ClinVar, PMID: 20301791). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
| Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Aug 29, 2022 | - - |
| Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 11, 2011 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Equipe Genetique des Anomalies du Developpement, Université de Bourgogne | - | - - |
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1 Pathogenic:4
| Pathogenic, criteria provided, single submitter | clinical testing | Genetics and Molecular Pathology, SA Pathology | Dec 13, 2022 | The POLG gene encodes the alpha subunit of polymerase gamma, a mitochondrial DNA polymerase. Pathogenic variants in POLG have been assocaited with Mitochondrial DNA depletion syndrome types 4A and 4B as well as autosomal dominant and recessive forms of Progressive external ophthalmoplegia (OMIM 174763). Variant Interpretation The POLG c.1399G>A missense variant is classified as PATHOGENIC (PS4, PM3, PS3, PP3) The POLG c.1399G>A missense variant is a single nucleotide change in exon 7 of the POLG gene, which is predicted to change the amino acid alanine at position 467 in the protein to threonine. This recurrent variant has been reported in both homozgous and compound heterozygous state in multiple patients with autosomal recessive progressive external ophthalmoplegia 1 (PMID: 11431686, 15824347) (PS4, PM3). Functional studies have demonstrated a significant reduction (96%) in gamma DNA polymerase enzyme activity in mutant cells compared with wild-type (PMID: 16024923) (PS3). This variant has been reported in dbSNP (rs113994095) and has been reported in population databases (gnomAD allele frequency = 0.048%, 143 het and 0 hom in 282888 sequenced alleles). this variant has been reported in ClinVar as pathogenic by multiple diagnostic laboratories (Variation ID: 13496). It has been reported as damaging for Progressive external ophthalmoplegia in the HGMD disease database (CM30938). Computational predictions support a deleterious effect on the gene or gene product (PP3). - |
| Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 11, 2011 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Mar 30, 2023 | This sequence change is predicted to replace alanine with threonine at codon 467 of the POLG protein (p.Ala467Thr). The alanine residue is highly conserved (100 vertebrates, UCSC), and is located in a helix within the linker region. There is a small physicochemical difference between alanine and threonine. The variant is present in a large population cohort at a frequency of 0.051%] (rs113994095, 143/282,888 alleles, 0 homozygotes in gnomAD v2.1). The variant is the most commonly reported POLG variant. It has been identified in the homozygous state and compound heterozygous with a second pathogenic allele in various POLG-related disorders, and segregates with disease in multiple families (PMID: 11431686, 15122711, 15917273, 21880868 - PM3_VeryStrong, PP1_Moderate). In vitro assays show reduced enzyme activity and DNA binding for the variant (PMID: 15917273, 16024923 - PS3_Supporting). Multiple lines of computational evidence predict a deleterious effect for the missense substitution (6/7 algorithms - PP3). Based on the classification scheme RMH ACMG Guidelines v1.2.1, this variant is classified as PATHOGENIC. Following criteria are met: PM3_VeryStrong, PP1_Moderate, PS3_Supporting, PP3. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Apr 24, 2014 | The Ala467Thr variant in POLG has been reported in >20 individuals with mitochondrial disease in both the homozygous and compound heterozygous states, with symptoms ranging from progressive external ophthalmoplegia to intractable epilepsy to Alpers syndrome (van Goethem 2001, van Goethem 2004, Ferrari 2005, Winterthun 2005, Lax 2012, Scalais 2012, Uusimaa 2012). This variant has also been identified in 0.14% (12/8598) of European American chromosomes and 0.09% (4/4400) of African American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/. In vitro functional studies have shown that the Ala467Thr variant leads to loss of wild-type activity and binding affinity (Chan 2005, Luoma 2005). In summary, this variant meets our criteria to be classified as pathogenic (http://pcpgm.partners.org/LMM). - |
POLG-related disorder Pathogenic:3Other:1
| not provided, no classification provided | phenotyping only | GenomeConnect, ClinGen | - | GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Undiagnosed Diseases Network, NIH | Jun 27, 2018 | Submitting this as a novel interpretation as this patient's phenotype does not fit any of the POLG-associated conditions listed in OMIM. This is a different observation than SCV000837701.1 where we observed this variant in a compound heterozygous state with another POLG variant and the patient fit the POLG-related conditions listed in OMIM. - |
| Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 09, 2024 | The POLG c.1399G>A variant is predicted to result in the amino acid substitution p.Ala467Thr. This variant has commonly been reported to be causative for autosomal recessive POLG-related disorders (Rajakulendran et al. 2016. PubMed ID: 26735972; Saneto et al. 2010. PubMed ID: 20138553; Van Goethem et al. 2001. PubMed ID: 11431686; Ferrari et al. 2005. PubMed ID: 15689359; Chan et al. 2005. PubMed ID: 16024923). In vitro functional studies have shown that this variant leads to loss of activity and binding affinity (Chan et al. 2005. PubMed ID: 16024923; Luoma et al. 2005. PubMed ID: 15917273; Kasahara et al. 2017. PubMed ID: 27987238). This variant is reported in 0.098% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
| Pathogenic, criteria provided, single submitter | research | UNC Molecular Genetics Laboratory, University of North Carolina at Chapel Hill | - | The POLG c.1399G>A (p.A467T) variant is the most common POLG variant associated with autosomal recessive Alpers-Huttenlocher syndrome (characterized by seizures, loss of mental and movement abilities, and liver disease PMID: 20301791). - |
Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis Pathogenic:3
| Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München | Nov 08, 2018 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Aug 04, 2022 | ACMG classification criteria: PS4 strong, PM3 very strong, PP1 strong, PP3 supporting, PP4 - |
| Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 11, 2011 | - - |
POLG-Related Spectrum Disorders Pathogenic:2
| Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 06, 2022 | Variant summary: POLG c.1399G>A (p.Ala467Thr) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00051 in 251484 control chromosomes (gnomAD). c.1399G>A has been reported in the literature as a biallelic genotype in multiple individuals affected with POLG-Related Spectrum Disorders (e.g. Van Goethem_2003, Luoma_2005, Winterthun_2005, Kollberg_2006). These data indicate that the variant is very likely to be associated with disease. Functional analysis using purified recombinant protein showed the variant had reduced binding affinity to DNA and reduced DNA synthesis activity (14% and 18% of controls, respectively. Luoma_2005). Twenty-five ClinVar submitters have assessed the variant since 2014: all classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1 Pathogenic:2
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 26, 2020 | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. Both variants have been previously reported as disease-causing [PMID 19578034 etc.] - |
| Pathogenic, criteria provided, single submitter | clinical testing | Courtagen Diagnostics Laboratory, Courtagen Life Sciences | Dec 16, 2013 | - - |
Mitochondrial disease Pathogenic:1Other:1
| Pathogenic, no assertion criteria provided | clinical testing | Wellcome Centre for Mitochondrial Research, Newcastle University | Apr 07, 2017 | - - |
| not provided, no classification provided | literature only | GeneReviews | - | - - |
Neurodevelopmental delay Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Centre de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille | - | - - |
Progressive sclerosing poliodystrophy;C1834846:Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1;C1843851:Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis;C3150914:Mitochondrial DNA depletion syndrome 4b;C4225153:Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1;C4551995:Mitochondrial DNA depletion syndrome 1 Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Dec 28, 2021 | - - |
Inborn genetic diseases Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 22, 2021 | The c.1399G>A (p.A467T) alteration is located in exon 7 (coding exon 6) of the POLG gene. This alteration results from a G to A substitution at nucleotide position 1399, causing the alanine (A) at amino acid position 467 to be replaced by a threonine (T). Based on the available evidence, this alteration is classified as pathogenic for autosomal recessive POLG-related mitochondrial disorders; however, the association of this alteration with autosomal dominant progressive external ophthalmoplegia is unlikely. Based on data from gnomAD, the A allele has an overall frequency of 0.05% (143/282888) total alleles studied. The highest observed frequency was 0.1% (127/129190) of European (non-Finnish) alleles. This mutation is the most common recessive pathogenic mutation found in POLG and accounts for 31% of all mutant alleles (Tang, 2011). This mutation has been identified in both compound heterozygous and homozygous states in many individuals presenting with a wide range of mitochondrial disorders, including but not limited to: Alpers syndrome, juvenile spinocerebellar ataxia-epilepsy syndrome, progressive external ophthalmoplegia, and other POLG-related disorders including ataxia, neuropathy, epilepsy, hepatopathy, and myopathy (Chan, 2005; Tang, 2011; Van Goethem, 2001; Van Goethem, 2004; Luoma, 2005; Janssen, 2016; Rajakulendran, 2016). This amino acid position is highly conserved in available vertebrate species. In vitro functional studies demonstrate that the p.A467T mutation results in 4-20% of wild-type DNA polymerase activity and fails to interact with the catalytic accessory subunit resulting in compromised catalytic activity (Chan, 2005). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
Hereditary spastic paraplegia Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | May 01, 2020 | - - |
Spinocerebellar ataxia with epilepsy Pathogenic:1
| Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 11, 2011 | - - |
Mitochondrial DNA depletion syndrome 4b Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | May 07, 2019 | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PS1,PS3,PM2,PM3,PP3. - |
Progressive sclerosing poliodystrophy;C1843851:Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis;C3150914:Mitochondrial DNA depletion syndrome 4b;C4225153:Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1 Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Aug 23, 2021 | PS3, PS4, PM1, PM3, PP3 - |
Tip-toe gait Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Practice for Gait Abnormalities, David Pomarino, Competency Network Toe Walking c/o Practice Pomarino | Nov 08, 2018 | Hereditary motor sensory neuropathy (HMSN), also known as Charcot-Marie-Tooth Disease (CMT), is the most commonly inherited peripheral polyneuropathy. It constitutes a group of inherited, progressive, motor and sensory peripheral nerve disorders with properties of demyelination, axonal degeneration, or both. It is classified by clinical characteristics, modes of inheritance, electrophysiologic features, metabolic defects, and specific gene markers. Our patients all walk on tiptoe, so they show similar symptoms. When we genetically test them with our toe walking panel, we find that around 90 per cent of them have a genetic variant that explains their toe walking. These can be assigned, for example, to the area of myopathies (such as variants of the COL6A3 gene), the area of hereditary neuropathies (such as variants of the KMT2C gene) or the area of metabolic diseases (such as variants of the PYGM gene). In a smaller group of patients with almost identical symptoms, no abnormality is found in the genes of our panel, but spastic paraplegia can be detected. In another small group of our toe walkers, no abnormalities can be detected in the genes analysed in our toe walking panel, nor do they suffer from spastic paraplegia, as is also the case with healthy children. In contrast to these, however, they show a tiptoe gait. These patients suffer from infantile cerebral palsy, in which toe walking can also be observed. - |
Progressive sclerosing poliodystrophy;C1834846:Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1;C1843851:Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis;C3150914:Mitochondrial DNA depletion syndrome 4b;C4225153:Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1 Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | Jul 21, 2020 | This variant has been previously reported as a homozygous and a compound heterozygous change in multiple patients and reported to segregate in several families affected by autosomal recessive POLG-related disorders including Alpers-Huttenlocher syndrome (AHS), progressive ataxic neuropathy, Parieto-occipital lobe epilepsy and Mitochondrial neurogastrointestinal encephalomyopathy-like syndrome (PMID: 11431686, 26735972, 15122711, 25286830, 20691285, 15917273). This is the most common AHS-causing variant in the POLG gene. Functional characterization indicates that the p.Ala467Thr variant, which is located near the exonuclease domain in the early linker region of the protein, severely reduces DNA polymerase gamma activity (down to 4% of wild type activity) by compromising the catalytic efficiency of the POLG protein (PMID: 16024923, 15917273). In addition, p.Ala467Thr fails to associate with the POLG2 accessory subunit, which leads to stalling at the replication fork and depletion of mtDNA over time (PMID: 16024923, 27987238, 16368709). The p.Ala467Thr variant is present in the heterozygous state in the gnomAD population database at a frequency of 0.051% (143/282888) and thus is presumed to be rare. In silico analyses support a deleterious effect of the c.1399G>A (p.Ala467Thr) variant on protein function. Based on the available evidence, the c.1399G>A (p.Ala467Thr) variant is classified as Pathogenic. - |
Progressive sclerosing poliodystrophy;C3150914:Mitochondrial DNA depletion syndrome 4b Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D;D
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
.;T
M_CAP
Uncertain
D
MetaRNN
Uncertain
D;D
MetaSVM
Uncertain
D
MutationAssessor
Benign
M;M
MutationTaster
Benign
A;A
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;D
REVEL
Pathogenic
Sift
Uncertain
D;D
Sift4G
Uncertain
T;T
Polyphen
D;D
Vest4
MVP
MPC
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at